Background Gastritis is a common condition affecting nearly half the world’s population. The Standard treatments like proton pump inhibitors have limitations such as adverse effects, frequent relapses, and growing antibiotic resistance in H. pylori. New therapies such as CKD-495 could offer safer and more effective alternatives by addressing these challenges.

Data Sources We conducted a systematic review and meta-analysis following PRISMA guidelines. Detailed Searches were performed in PubMed, Scopus, Embase, and ClinicalTrials.gov up to April 2025. Additional studies were identified through bibliographic mining and citation searches.

Main Findings and Limitations Two randomized controlled trials (total N=475) that compare CKD-495 with Artemisiae argyi folium (AAF) met inclusion criteria. The meta-analysis showed that CKD-495 significantly improved rates of erosion healing (OR≈2.1; P=0.001) compared to AAF. There was no increase in adverse events. The risk of bias was low across all domains. limitations include the small number of studies, limited sample sizes, and short follow-up periods restrict the generalizability of the findings.

Conclusions CKD-495 appears to be a promising alternative for treating gastritis. this study demonstrates the better mucosal healing with similar safety compared to AAF. Further large, multicenter trials are needed to confirm these results and evaluate long-term outcomes.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study used (or will use) ONLY openly available human data on public databases and websites (e.g. Journal Websites, PubMed, Embase etc.)

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors